Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

143.53 +0.26 (+0.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,194,466
Open 142.31
Bid (Size) 137.52 (1)
Ask (Size) 146.00 (1)
Prev. Close 143.27
Today's Range 140.89 - 143.67
52wk Range 99.06 - 148.06
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory

Performance

YTD
+15.97%
+15.97%
1 Month
+14.78%
+14.78%
3 Month
+18.05%
+18.05%
6 Month
+31.29%
+31.29%
1 Year
+20.77%
+20.77%

More News

Read More
Viatris Earnings: What To Look For From VTRS
Via StockStory
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Earnings Scheduled For February 25, 2025
Via Benzinga
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Via Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Via StockStory
NASDAQ:JAZZ is probably undervalued for the fundamentals it is displaying.
Via Chartmill
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents.
Via Chartmill
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Via Chartmill
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
Via Benzinga
NASDAQ:JAZZ is an undervalued gem with solid fundamentals.
Via Chartmill
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
Via Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Via Benzinga
Exposures Product Safety
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Via Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Via The Motley Fool
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.